Wegovy risk factors: separating real concerns from common myths

The myth that concerns most people, and why it's only half true

The fear circulating online is that Wegovy causes serious harm routinely. It doesn't. The STEP 1 trial, published in the New England Journal of Medicine, followed nearly 2,000 adults for 68 weeks and found the side-effect profile was dominated by gastrointestinal symptoms: nausea, loose stools, vomiting, constipation. These effects are real, they affect a meaningful proportion of users, and they can be unpleasant, but they are typically front-loaded around dose increases and settle as the body adjusts. Serious adverse events were uncommon in the trial population. So the myth isn't that Wegovy has risks. It's that those risks are uniformly severe, or that the medicine is safe for everyone regardless of their starting health. Neither is accurate.

Certain conditions do raise genuine concerns. A personal or family history of medullary thyroid carcinoma, or a diagnosis of Multiple Endocrine Neoplasia syndrome type 2 (MEN2), places Wegovy outside its licensed indication entirely. Active pancreatitis (or a significant history of it) is another reason a prescriber may not proceed. Severe gastrointestinal disease, including gastroparesis, also warrants careful prescriber review. These aren't bureaucratic boxes; they reflect the pharmacology of a GLP-1 receptor agonist working on gut motility and hormone signalling. Understanding the full risk picture for Wegovy helps set realistic expectations before the consultation.

The side effects that deserve attention vs. the ones that just need patience

A practical question worth five seconds of your time: when you start a new dose, note the date on your phone. That timestamp helps you and your prescriber judge whether any discomfort is the expected early-week settling or something that has gone on too long.

Nausea is the most commonly reported effect and is the reason the starting dose is kept low, the first four weeks are about letting your system adapt, not about weight-loss momentum. Headache, fatigue, burping and indigestion are also common in the early weeks. These effects are covered in detail on the Wegovy side effects page, including practical ways to manage them at meal times. What separates ordinary discomfort from a signal requiring medical input is intensity and duration: mild nausea that peaks on day two of a new dose and then eases is expected. Persistent vomiting that prevents you drinking fluids, or severe abdominal pain, is not.

Gallbladder problems (including gallstones) have been reported with semaglutide. Rapid weight loss itself carries this risk, so the medicine and the weight change interact here. Symptoms of a gallbladder episode include pain in the upper-right abdomen, sometimes with fever. That needs same-day medical review, not a wait-and-see approach. People who have had gallbladder issues previously should make sure their prescriber knows before starting.

When to get medical help, and where to report concerns

Three patterns need prompt attention. First: severe, persistent stomach pain spreading toward the back, with or without vomiting. This is the presentation that raised concern in the MHRA's January 2026 Drug Safety Update on GLP-1 medicines and acute pancreatitis. It's infrequent, but it's serious enough that waiting to see if it passes is not the right call. Go to urgent care or call 111.

Second: symptoms of a serious allergic reaction, swelling of the face, lips or throat, difficulty breathing, severe skin reactions. Stop the injection and seek emergency help.

Third: signs of severe dehydration from persistent GI illness, dizziness on standing, very little or no urine, rapid heartbeat. Sustained vomiting or diarrhoea can cause kidney problems if fluid losses aren't replaced, so hydration during any GI flare genuinely matters.

Beyond these urgent situations, any suspected side effect from Wegovy can be reported to the MHRA using the Yellow Card reporting scheme. Patients can submit reports directly, it takes a few minutes and contributes to post-market safety monitoring for a Black Triangle medicine still under active surveillance. For broader context on the cancer-related questions some patients raise, the Wegovy and cancer risk page addresses what the evidence does and doesn't show.

Who faces higher background risk, and what the consultation covers

Risk factors aren't just about contraindications. Some people start with a higher baseline likelihood of experiencing particular effects. Those with a history of mood disorders, for example, are encouraged to monitor their mental health during treatment, low mood or thoughts of self-harm should prompt contact with a prescriber promptly. People with type 2 diabetes taking insulin or sulfonylureas alongside Wegovy face a higher risk of hypoglycaemia; dose adjustments of the diabetes medicine are often needed. That's a prescriber decision, not a self-managed one.

Age, kidney function and cardiovascular history all feed into the overall picture. Wegovy actually holds a UK licence for reducing major cardiovascular event risk in eligible adults, which means it isn't simply avoided in people with heart disease, but it does mean the full health history matters at assessment. Some patients also want to understand what the evidence says about Wegovy and blindness risk before committing to treatment, and that page sets out the current clinical picture clearly. The weighing-up page on whether Wegovy is worth the risk looks at this balance in more depth. At nume, our prescribers cover these factors as part of every consultation, the process exists precisely because a blanket rule can't replace an individual clinical read. If you'd like to discuss your specific history, check your eligibility through our free consultation. You can also read more about Wegovy as a treatment or explore weight-loss treatment options more broadly before deciding.